Andrew David Bergemann

US Patent:

56724799, Sep 30, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/486421

Inventors:

Edward M. Johnson - New York NY
Andrew D. Bergemann - Boston MA

Assignee:

Mount Sinai School of Medicine - New York NY

International Classification:

G01N 3353
G01N 33574
C07K 200
C12N 1500

US Classification:

435 71

Abstract:

The present invention relates to the PUR protein, nucleotide sequences and expression vectors encoding PUR, and to methods for inhibiting PUR activity. Inhibitors of PUR activity may be used to treat hyperproliferative diseases such as cancer.

US Patent:

57566844, May 26, 1998

Filed:

Jun 6, 1995

Appl. No.:

8/470911

Inventors:

Edward M. Johnson - New York NY
Andrew D. Bergemann - Boston MA

Assignee:

Mount Sinai School of Medicine of the City of New York - New York NY

International Classification:

C07K 900
C12N 900
C12N 1512

US Classification:

53038821

Abstract:

The present invention relates to the PUR protein, nucleotide sequences and expression vectors encoding PUR, and to methods for inhibiting PUR activity. Inhibitors of PUR activity may be used to treat hyperproliferative diseases such as cancer.

US Patent:

58696229, Feb 9, 1999

Filed:

Jun 7, 1995

Appl. No.:

8/486809

Inventors:

Edward M. Johnson - New York NY
Andrew D. Bergemann - Boston MA

Assignee:

Mount Sinai School of Medicine of the City University of New York - New York NY

International Classification:

C07K 1600

US Classification:

53038885

Abstract:

The present invention relates to the PUR protein, nucleotide sequences and expression vectors encoding PUR, and to methods for inhibiting PUR activity. More specifically, the invention relates to polyclonal and monoclonal antibodies that bind PUR or PUR related proteins. Antibodies that bind PUR protein and which neutralize. PUR activity may be used to treat hyperproliferative diseases such as cancer.